Skip to content
DraconiticResearch
Search Sources API
203,234 studies31 sourcesUpdated 48 min ago
Peer-reviewedCC BYFrontiers in aging neuroscience

Epigenetics in Alzheimer's disease: from molecular mechanisms to emerging novel biomarkers.

  • Elisabetta D'Aversa1,2
  • Miriana Grisafi1
  • Salvatore Pernagallo3
  • Francesca Salvatori1
  • Ajay V Singh4
  • Alessia Nucciarone1
  • Veronica Tisato1,2,5,6
  • Donato Gemmati1,2,5
6 affiliations
  1. 1Department of Translational Medicine, University of Ferrara, Ferrara, Italy.
  2. 2Center for Hemostasis and Thrombosis, University of Ferrara, Ferrara, Italy.
  3. 3Department of Environmental Sciences and Prevention, University of Ferrara, Ferrara, Italy.
  4. 4Department of Chemical and Product Safety, German Federal Institute for Risk Assessment (BfR), Berlin, Germany.
  5. 5University Strategic Centre for Studies on Gender Medicine, University of Ferrara, Ferrara, Italy.
  6. 6LTTA Center, University of Ferrara, Ferrara, Italy.
Read full textPDFDOICite

Abstract

Alzheimer's disease (AD) is an age-related progressive neurodegenerative disorder that represents the leading cause of dementia worldwide, affecting over 50 million people. This global burden is expected to rise dramatically over the coming decades because of global population aging, representing a public health concern. Despite significant advances in understanding AD pathophysiology, early diagnosis remains challenging, emphasizing the urgent need for novel, reliable diagnostic and predictive biomarkers capable of identifying individuals at risk of progression during the preclinical stages of the disease. Growing evidence indicates that epigenetics constitutes a dynamic interface through which aging and environmental exposures influence gene expression and cellular homeostasis, thereby contributing to AD susceptibility and progression. The present review summarizes current knowledge on the epigenetic landscape of AD, from canonical epigenetic mechanisms, including aberrant DNA methylation, histone modifications, and non-coding RNAs (ncRNAs), to the emerging role of mitoepigenetics and RNA methylation in disease-associated molecular mechanisms. Finally, we discuss the potential of epigenetic alterations as promising innovative biomarkers of AD, providing insights into novel avenues for diagnostic and therapeutic intervention.

Related

  1. Mitochondrial Dysfunction in Diabetic Neuropathy: An Evidence Map of Molecular Mechanisms, Translational Biomarkers, and Emerging Implications for Oral Neuropathy-A Scoping Review.
    Kurnia Hayati Rahman, Ujjal K Bhawal, Jian Wang +2
    International journal of molecular sciencesPeer-reviewedCC BYFull textPhysiologyEurope PMC
  2. Tryptophan Metabolism in Pediatric Atopic Dermatitis: Shared Mechanisms, Age-Specific Biomarkers, and Emerging Therapies
    Marta Dyszkiewicz, Beata Cudowska, Wioleta Justyna Omeljaniuk +2
    BiomedicinesPeer-reviewedCC BYFull textGeneral medicineEurope PMC
  3. Neuroinflammation in Alzheimer’s disease: pathogenic signaling, biomarkers, and emerging therapeutic interventions
    Poonam, Rekha Rana, Mohita Thakur +8
    Frontiers in OncologyPeer-reviewedCC BY 4.0Full textNeurologyCrossrefDOAJEurope PMC
  4. Interleukin-Driven Inflammation and Cardiovascular Risk in People Living with HIV: Mechanisms, Biomarkers, and Emerging Preventive Strategies
    Asbiel Felipe Garibaldi-Ríos, Martha Patricia Gallegos-Arreola, Jesús Magdiel García-Díaz +9
    Medical sciences (Basel, Switzerland)Peer-reviewedCC BYFull textGeneral medicineEurope PMC
  5. Noninvasive diagnosis of Alzheimer's disease: a review of emerging biomarkers and multimodal approaches.
    Junsheng Zhao, Chenqi Nie, Rong Gao +2
    Frontiers in cell and developmental biologyPeer-reviewedCC BYFull textPsychiatry & mental healthEurope PMC

Cite

BibTeXRIS
BibTeX
@article{daversa2026epigenetics,
  title = {{Epigenetics in Alzheimer's disease: from molecular mechanisms to emerging novel biomarkers.}},
  author = {Elisabetta D'Aversa and Miriana Grisafi and Salvatore Pernagallo and Francesca Salvatori and Ajay V Singh and Alessia Nucciarone and Veronica Tisato and Donato Gemmati},
  journal = {Frontiers in aging neuroscience},
  year = {2026},
  month = oct,
  doi = {10.3389/fnagi.2026.1959361},
  url = {https://europepmc.org/article/MED/42899003},
  note = {CC BY},
}
RIS
TY  - JOUR
TI  - Epigenetics in Alzheimer's disease: from molecular mechanisms to emerging novel biomarkers.
AU  - Elisabetta D'Aversa
AU  - Miriana Grisafi
AU  - Salvatore Pernagallo
AU  - Francesca Salvatori
AU  - Ajay V Singh
AU  - Alessia Nucciarone
AU  - Veronica Tisato
AU  - Donato Gemmati
PY  - 2026
DA  - 2026/10/05
JO  - Frontiers in aging neuroscience
DO  - 10.3389/fnagi.2026.1959361
UR  - https://europepmc.org/article/MED/42899003
AB  - Alzheimer's disease (AD) is an age-related progressive neurodegenerative disorder that represents the leading cause of dementia worldwide, affecting over 50 million people. This global burden is expected to rise dramatically over the coming decades because of global population aging, representing a public health concern. Despite significant advances in understanding AD pathophysiology, early diagnosis remains challenging, emphasizing the urgent need for novel, reliable diagnostic and predictive biomarkers capable of identifying individuals at risk of progression during the preclinical stages of the disease. Growing evidence indicates that epigenetics constitutes a dynamic interface through which aging and environmental exposures influence gene expression and cellular homeostasis, thereby contributing to AD susceptibility and progression. The present review summarizes current knowledge on the epigenetic landscape of AD, from canonical epigenetic mechanisms, including aberrant DNA methylation, histone modifications, and non-coding RNAs (ncRNAs), to the emerging role of mitoepigenetics and RNA methylation in disease-associated molecular mechanisms. Finally, we discuss the potential of epigenetic alterations as promising innovative biomarkers of AD, providing insights into novel avenues for diagnostic and therapeutic intervention.
SN  - 1663-4365
ER  -